Get the Stockscreener App
0.88
11.93%
-0.0967
Scilex Holding Company stock is currently priced at $0.88, with a 24-hour trading volume of 5,503.
It has seen a -11.93% decreased in the last 24 hours and a -41.08% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9822 pivot point. If it approaches the $0.8445 support level, significant changes may occur.
Previous Close:
$0.9767
Open:
$0.8602
24h Volume:
5,503
Market Cap:
$90.20M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-1.4637
EPS:
-0.6012
Net Cash Flow:
$-21.04M
1W Performance:
-4.42%
1M Performance:
-41.08%
6M Performance:
-57.63%
1Y Performance:
-87.33%
1D Range:
$0.8602
$0.8602
52W Range:
$0.8002
$8.3699
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
650-516-4310
Address
960 San Antonio Road, Palo Alto
Scilex Holding Company Stock (SCLX) Latest News
Scilex Holding Company Announces $15 Million Registered Direct Offering
GlobeNewswire Inc.
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
GlobeNewswire Inc.
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
GlobeNewswire Inc.
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
GlobeNewswire Inc.
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
GlobeNewswire Inc.
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
GlobeNewswire Inc.
Scilex Holding Company Stock (SCLX) Financials Data
Scilex Holding Company (SCLX) Revenue 2024
SCLX reported a revenue (TTM) of $46.74 million for the quarter ending December 31, 2023, a +22.90% rise year-over-year.
Scilex Holding Company (SCLX) Net Income 2024
SCLX net income (TTM) was -$114.33 million for the quarter ending December 31, 2023, a -389.35% decrease year-over-year.
Scilex Holding Company (SCLX) Cash Flow 2024
SCLX recorded a free cash flow (TTM) of -$21.04 million for the quarter ending December 31, 2023, a +1.04% increase year-over-year.
Scilex Holding Company (SCLX) Earnings per Share 2024
SCLX earnings per share (TTM) was -$1.29 for the quarter ending December 31, 2023, a -646.53% decline year-over-year.
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
0.07%
0.27%
Cap:
|
Volume (24h):